IL6 and cancer: Finally, since biomarkers in body fluids may reflect the entire heterogeneity of cancerous tissue, a biomarker panel instead of a single biomarker may increase sensitivity and specificity.20 For example, a single biomarker like pro-inflammatory cytokine IL-6 or IL-8 that holds great promise is often not unique to TSCC, and no reference level of expression has been reached yet in cancer, so combining these markers, together or with other biomarkers, would likely provide a more robust clarification of true detection or prognosis.